Shi Binyu, Zhang You, Wu Shuo, Xu Dongsheng, Wu Qianyun, Jia Wenzhi, An Shuxian, Wang Cheng, Bai Yongrui, Liu Jianjun, Zhou Junjun, Wei Weijun
Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; and.
Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
J Nucl Med. 2025 Jun 2;66(6):865-872. doi: 10.2967/jnumed.125.269585.
CD70 has emerged as a promising biomarker for nasopharyngeal carcinoma (NPC). This study investigated CD70 expression patterns in NPC specimens and evaluated the diagnostic potential of CD70-targeted [F]RCCB6 immuno-PET/CT in patients with NPC. CD70 expression was analyzed in 80 archived NPC specimens and correlated with clinical and pathologic features. Using [F]RCCB6, a single-domain antibody-derived tracer specific for human CD70, the diagnostic efficacy of [F]RCCB6 immuno-PET/CT was assessed in 25 patients with NPC and compared with that of F-FDG PET/CT. CD70 was positively expressed in 72 (90%) of 80 NPC specimens, with expression levels strongly correlated with Epstein-Barr virus (EBV) titers (r = 0.437; < 0.001) and N-staging ( = 0.006). In all 15 patients with early-stage NPC, [F]RCCB6 immuno-PET/CT achieved a 100% detection rate of the primary tumor and a 93% detection rate (75/81) of local lymph node metastasis. [F]RCCB6 uptake correlated well with CD70 expression. In a head-to-head comparison, [F]RCCB6 demonstrated higher sensitivity than did F-FDG in detecting lymph node metastasis (100% [58/58] vs. 90% [52/58], respectively; = 0.031), and equivalent detection abilities for primary lesions and most distant metastases (100%). Notably, [F]RCCB6 immuno-PET/CT demonstrated better evaluation of skull-base invasion with a clear border and bone metastases, as indicated by its higher uptake compared with F-FDG (7.25 vs. 5.95; = 0.025). CD70 is a potent biomarker for NPC. [F]RCCB6 immuno-PET/CT provides precise mapping of CD70 expression and enhances the diagnosis of primary, metastatic, and recurrent NPCs, outperforming F-FDG in detecting skull-base invasion and metastases.
CD70已成为鼻咽癌（NPC）一种很有前景的生物标志物。本研究调查了NPC标本中CD70的表达模式，并评估了靶向CD70的[F]RCCB6免疫PET/CT在NPC患者中的诊断潜力。对80份存档的NPC标本进行了CD70表达分析，并将其与临床和病理特征相关联。使用[F]RCCB6（一种针对人CD70的单域抗体衍生示踪剂），评估了[F]RCCB6免疫PET/CT在25例NPC患者中的诊断效能，并与F-FDG PET/CT进行了比较。80份NPC标本中有72份（90%）CD70呈阳性表达，其表达水平与EB病毒（EBV）滴度（r = 0.437；P < 0.001）及N分期（P = 0.006）密切相关。在所有15例早期NPC患者中，[F]RCCB6免疫PET/CT对原发肿瘤的检出率为100%，对局部淋巴结转移的检出率为93%（75/81）。[F]RCCB6摄取与CD70表达密切相关。在直接比较中，[F]RCCB6在检测淋巴结转移方面显示出比F-FDG更高的敏感性（分别为100%[58/58]和90%[52/58]；P = 0.031），对原发灶和远处转移灶的检测能力相当（均为100%）。值得注意的是，[F]RCCB6免疫PET/CT对颅底侵犯和骨转移的评估更好，边界清晰，其摄取高于F-FDG（7.25对5.95；P = 0.025）。CD70是NPC的一种有效生物标志物。[F]RCCB6免疫PET/CT可精确显示CD70表达情况，提高对原发、转移及复发性NPC的诊断，在检测颅底侵犯和转移方面优于F-FDG。
